BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more

Graft Sculpting Brings New Approach to Stem Cell Therapy for Highest Risk AML Patients 

A novel hematopoietic stem cell transplantation (HSCT) method utilizing ‘graft sculpting’ is being tested in a phase 1 clinical trial in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are at the highest risk of relapse after ‘standard’ transplants. In fact, the patients in the trial don’t qualify for a standard … Read more

Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia: What to Know

Drugs known as tyrosine kinase inhibitors, or TKIs, have revolutionized the treatment of chronic myelogenous leukemia (CML), a type of cancer in which the bone marrow produces too many semi-mature white blood cells. Prior to the introduction of these drugs in the early 2000s, standard first-line treatments for the disease reduced CML levels in only … Read more

Study Explores Inequities in Acute Leukemia Clinical Trial Participation

While some racial and ethnic groups have been underrepresented in clinical trials of therapies for lung cancer, breast cancer and other malignancies, researchers speculated that the situation might be different for adult leukemia trials. The unique features of the disease — the speed with which it needs to be treated after diagnosis, the delivery of … Read more

Specially Equipped Natural Killer Cells Show Promise Against Form of AML

CAR T cells’ superpower is to identify cancer-related targets on the surface of tumor cells and order an attack on those cells. But they lack anything resembling X-ray vision to detect nefarious protein targets within tumor cells. That shortfall has limited their effectiveness in diseases like acute myelogenous leukemia (AML), in which tumor cells display few surface … Read more

Seeking Stem Cell Transplant, Basketball Expert Makes Slam Dunk Decision

As an economist specializing in statistical analysis, Dan Rosenbaum has done everything from help the federal government use more evidence in its decision-making to assist several National Basketball Association (NBA) teams in finding and signing the best players. Research and number-crunching are his expertise, so when Rosenbaum learned he needed a life-saving stem cell transplant … Read more

High School Basketball Coach has a New Perspective on Life After a Successful Stem Cell Transplant

For Duane Witter, the most difficult part of his cancer treatment was recovering from his stem cell transplant and having to step away from teaching and coaching high school basketball in Farmington, CT. “Before all this, I used to say that my superpower was to never miss a day of school,” he says. “Stepping away … Read more

Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia

Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators. The addition of the targeted drug venetoclax to a chemo regimen called R-EPOCH yielded the … Read more

Anti-Microbial Drug Targets Key Driver of Chronic Lymphocytic Leukemia

Dana-Farber scientists have found that a generic anti-microbial drug can block a key molecular driver of chronic lymphocytic leukemia (CLL) cells, and when tested in a small clinical trial of advanced CLL patients who had relapsed, the drug slowed disease progression in half of them. The drug, pyrimethamine, achieved stable disease in eight of the … Read more

For Young Mom with Chronic Lymphocytic Leukemia, Clinical Trial is a Life-Saver

As head of marketing for a leading international news agency, Kelly Ives routinely worked with journalists across the globe. When it came to chronic lymphocytic leukemia (CLL), however, it was her own reporting skills that led Ives to a life-changing treatment. Ives was a 37-year-old mom with a career and three young children, including an … Read more

What is the Role of Genetics in Lymphoma and Chronic Lymphocytic Leukemia?

Studies in large populations have shown that people who have a near relative with a form of lymphoma or chronic lymphocytic leukemia (CLL) have an increased risk of developing these diseases themselves. Both lymphoma and CLL are relatively uncommon: the average person’s lifetime risk of developing CLL, for example, is 0.57%, according to the American … Read more

Patient with Cancer Shares Tips for Being Your Biggest Advocate

Life is like a Mad-Lib, and Jennifer White is taking control of what she can fill in the blank spaces. The Atlanta-based cyber security consultant was diagnosed with chronic lymphocytic leukemia (CLL) in January 2019. In July of that same year, White, a Boston native, came to Dana-Farber. She currently comes to Boston four times … Read more

Study Reveals Promising Combination Therapy for T-Cell Prolymphocytic Leukemia

Cancer cells have a bias toward survival, often becoming heavily reliant on certain protein pathways to sustain themselves. Scientists are finding ways to turn that survival instinct into a liability — by making the cells even more dependent on those pathways, then choking the pathways off. It’s an approach that has now yielded a promising … Read more

Venetoclax Combination Approved for Older Patients with AML

The U.S. Food and Drug Administration (FDA) approved a novel targeted drug to treat acute myelogenous leukemia (AML) in older patients, a segment of the blood cancer population in dire need of improved therapies. In a phase 3 clinical trial, researchers showed that the oral drug, venetoclax (or Venclexta), when given along with azacitidine, could … Read more

What Are the Differences Between Lymphocytic and Myelogenous Leukemia?

Medically reviewed by Martha Wadleigh, MD Leukemia arises from malfunctions in stem cells within the bone marrow that cause abnormal white blood cells to flood into the bloodstream. Leukemias are classified as either myelogenous (also called myeloid) or lymphocytic, depending on which types of white blood cells are affected. What is the difference between these types … Read more